Disseminated Breast Cancer Cells Acquire a Highly Malignant and Aggressive Metastatic Phenotype during Metastatic Latency in the Bone

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Marsden, Carolyn G ^a   Wright, Mary Jo ^b   Carrier, Latonya ^a   Moroz, Krzysztof ^b   Rowan, Brian G ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; BONE METASTASIS; BREAST; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CONTROLLED STUDY; DISEASE MARKER; DISSEMINATED CANCER; EPITHELIUM; FEMALE; IMMUNOHISTOCHEMISTRY; KIDNEY; LATENT PERIOD; LIVER; LUNG; MESENCHYME; MOUSE; NONHUMAN; NUDE MOUSE; PHENOTYPE; PROTEIN EXPRESSION;

ADIPOSE TISSUE; ANIMALS; BONE MARROW; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; INJECTIONS; MAMMARY GLANDS, ANIMAL; MICE; NEOPLASM METASTASIS; PHENOTYPE; TUMOR MICROENVIRONMENT;

MUS; MUS MUSCULUS;

EID: 84869231495     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047587     Document Type: Article

References (73)

1. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, et al. (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13: 58-68.
2. Engel J, Eckel R, Kerr J, Schmidt M, Furstenberger G, et al. (2003) The process of metastasisation for breast cancer. Eur J Cancer 39: 1794-1806.
3. van 't Veer LJ, Dai H, Van De Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
4. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, et al. (2003) From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A 100: 7737-7742.
5. Coleman RE, (1997) Skeletal complications of malignancy. Cancer 80: 1588-1594.
6. Diel IJ, Kaufmann M, Costa SD, Holle R, von MG, et al. (1996) Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 88: 1652-1658.
7. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, et al. (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353: 793-802.
8. Gebauer G, Fehm T, Merkle E, Beck EP, Lang N, et al. (2001) Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 19: 3669-3674.
9. Wiedswang G, Borgen E, Karesen R, Naume B, (2003) Detection of isolated tumor cells in BM from breast-cancer patients: significance of anterior and posterior iliac crest aspirations and the number of mononuclear cells analyzed. Cytotherapy 5: 40-45.
10. Bidard FC, Vincent-Salomon A, Gomme S, Nos C, de RY, et al. (2008) Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res 14: 3306-3311.
11. Allgayer H, Aguirre-Ghiso JA, (2008) The urokinase receptor (u-PAR)-a link between tumor cell dormancy and minimal residual disease in bone marrow? APMIS 116: 602-614.
12. Karrison TG, Ferguson DJ, Meier P, (1999) Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 91: 80-85.
13. Wiedswang G, Borgen E, Karesen R, Qvist H, Janbu J, et al. (2004) Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 10: 5342-5348.
14. Pantel K, Brakenhoff RH, (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4: 448-456.
15. Nicola MH, Bizon R, Machado JJ, Sollero T, Rodarte RS, et al. (2003) Breast cancer micrometastases: different interactions of carcinoma cells with normal and cancer patients' bone marrow stromata. Clin Exp Metastasis 20: 471-479.
16. Klein CA, Holzel D, (2006) Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics. Cell Cycle 5: 1788-1798. 3097 [pii].
17. Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, et al. (2002) Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360: 683-689.
18. Schardt JA, Meyer M, Hartmann CH, Schubert F, Schmidt-Kittler O, et al. (2005) Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 8: 227-239.
19. Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, et al. (2007) Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol 1: 160-171.
20. Habeck M, (2000) Bone-marrow analysis predicts breast-cancer recurrence. Mol Med Today 6: 256-257.
21. Rao G, Patel PS, Idler SP, Maloof P, Gascon P, et al. (2004) Facilitating role of preprotachykinin-I gene in the integration of breast cancer cells within the stromal compartment of the bone marrow: a model of early cancer progression. Cancer Res 64: 2874-2881.
22. Lim PK, Bliss SA, Patel SA, Taborga M, Dave MA, et al. (2011) Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res 71: 1550-1560.
23. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, et al. (2009) Tumor self-seeding by circulating cancer cells. Cell 139: 1315-1326.
24. Leung CT, Brugge JS, (2009) Tumor self-seeding: bidirectional flow of tumor cells. Cell 139: 1226-1228.
25. Marsden CG, Wright MJ, Carrier L, Moroz K, Pochampally R, et al. (2012) "A novel in vivo model for the study of human breast cancer metastasis using primary breast tumor-initiating cells from patient biopsies". BMC Cancer 12: 10.
26. Marsden CG, Wright MJ, Pochampally R, Rowan BG, (2009) Breast tumor-initiating cells isolated from patient core biopsies for study of hormone action. Methods Mol Biol 590: 363-375.
27. Dontu G, Al Hajj M, Abdallah WM, Clarke MF, Wicha MS, (2003) Stem cells in normal breast development and breast cancer. Cell Prolif 36 (Suppl 1):: 59-72.
28. Anbalagan M, Ali A, Jones RK, Marsden CG, Sheng M, et al. (2012) Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts. Mol Cancer Ther pp. 1535-7163.
29. Schmalhofer O, Brabletz S, Brabletz T, (2009) E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 28: 151-166.
30. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, et al. (2007) Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 213: 374-383.
31. Feuerer M, Rocha M, Bai L, Umansky V, Solomayer EF, et al. (2001) Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. Int J Cancer 92: 96-105.
32. Siclari VA, Guise TA, Chirgwin JM, (2006) Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev 25: 621-633.
33. Phadke PA, Mercer RR, Harms JF, Jia Y, Frost AR, et al. (2006) Kinetics of metastatic breast cancer cell trafficking in bone. Clin Cancer Res 12: 1431-1440.
34. Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, et al. (2005) Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer 5 (Suppl):: S46-S53.
35. Kozlow W, Guise TA, (2005) Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 10: 169-180.
36. Kopp HG, Avecilla ST, Hooper AT, Rafii S, (2005) The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology (Bethesda) 20: 349-356.
37. Scadden DT, (2006) The stem-cell niche as an entity of action. Nature 441: 1075-1079.
38. Morrison SJ, Spradling AC, (2008) Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell 132: 598-611.
39. Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, et al. (2004) Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118: 149-161.
40. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, et al. (2003) Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425: 841-846.
41. Nilsson SK, Johnston HM, Coverdale JA, (2001) Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches. Blood 97: 2293-2299.
42. Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, et al. (2006) Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 12: 557-567.
43. Abkowitz JL, Robinson AE, Kale S, Long MW, Chen J, (2003) Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. Blood 102: 1249-1253.
44. Bussard KM, Gay CV, Mastro AM, (2008) The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev 27: 41-55.
45. Fehm T, Krawczyk N, Solomayer EF, Becker-Pergola G, Durr-Storzer S, et al. (2008) ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res 10: R76.
46. Ditsch N, Mayer B, Rolle M, Untch M, Schildberg FW, et al. (2003) Estrogen receptor expression profile of disseminated epithelial tumor cells in bone marrow of breast cancer patients. Recent Results Cancer Res 162: 141-147.
47. Berx G, Van Roy F, (2001) The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 3: 289-293.
48. Prasad CP, Rath G, Mathur S, Bhatnagar D, Parshad R, et al. (2009) Expression analysis of E-cadherin, Slug and GSK3beta in invasive ductal carcinoma of breast. BMC Cancer 9: 325.
49. Kowalski PJ, Rubin MA, Kleer CG, (2003) E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 5: R217-R222.
50. Polyak K, Weinberg RA, (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273.
51. Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, et al. (2001) ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 61: 1890-1895.
52. Pachmann K, Clement JH, Schneider CP, Willen B, Camara O, et al. (2005) Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med 43: 617-627.
53. Elston MS, Gill AJ, Conaglen JV, Clarkson A, Cook RJ, et al. (2009) Nuclear accumulation of e-cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas. J Clin Endocrinol Metab 94: 1436-1442.
54. Salahshor S, Naidoo R, Serra S, Shih W, Tsao MS, et al. (2008) Frequent accumulation of nuclear E-cadherin and alterations in the Wnt signaling pathway in esophageal squamous cell carcinomas. Mod Pathol 21: 271-281.
55. Han AC, Soler AP, Tang CK, Knudsen KA, Salazar H, (2000) Nuclear localization of E-cadherin expression in Merkel cell carcinoma. Arch Pathol Lab Med 124: 1147-1151.
56. Chetty R, Serra S, (2008) Membrane loss and aberrant nuclear localization of E-cadherin are consistent features of solid pseudopapillary tumour of the pancreas. An immunohistochemical study using two antibodies recognizing different domains of the E-cadherin molecule. Histopathology 52: 325-330.
57. Chetty R, Serra S, Salahshor S, (2008) E-cadherin in solid pseudopapillary tumors of the pancreas. Hum Pathol 39: 1407-1408.
58. Gervais ML, Henry PC, Saravanan A, Burry TN, Gallie BL, et al. (2007) Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma. Lab Invest 87: 1252-1264.
59. Ohishi Y, Oda Y, Kurihara S, Kaku T, Kobayashi H, et al. (2011) Nuclear localization of E-cadherin but not beta-catenin in human ovarian granulosa cell tumours and normal ovarian follicles and ovarian stroma. Histopathology 58: 423-432.
60. Sauer T, Boudjema G, Jebsen PW, Naess O, (2001) Immunocytochemical expression of E-cadherin on fine-needle aspirates from breast carcinomas correlate with the cell dissociation pattern seen on smears. Diagn Cytopathol 25: 382-388.
61. Salahshor S, Haixin L, Huo H, Kristensen VN, Loman N, et al. (2001) Low frequency of E-cadherin alterations in familial breast cancer. Breast Cancer Res 3: 199-207.
62. Cardamone MD, Bardella C, Gutierrez A, Di CL, Rosenfeld MG, et al. (2009) ERalpha as ligand-independent activator of CDH-1 regulates determination and maintenance of epithelial morphology in breast cancer cells. Proc Natl Acad Sci U S A 106: 7420-7425.
63. Lombaerts M, van Wezel T, Philippo K, Dierssen JW, Zimmerman RM, et al. (2006) E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer 94: 661-671.
64. Hajra KM, Chen DY, Fearon ER, (2002) The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 62: 1613-1618.
65. Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, et al. (2002) A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J 21: 1948-1956.
66. Wheelock MJ, Buck CA, Bechtol KB, Damsky CH, (1987) Soluble 80-kd fragment of cell-CAM 120/80 disrupts cell-cell adhesion. J Cell Biochem 34: 187-202.
67. Najy AJ, Day KC, Day ML, (2008) The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem 283: 18393-18401.
68. Haas IG, Frank M, Veron N, Kemler R, (2005) Presenilin-dependent processing and nuclear function of gamma-protocadherins. J Biol Chem 280: 9313-9319.
69. Marambaud P, Wen PH, Dutt A, Shioi J, Takashima A, et al. (2003) A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell 114: 635-645.
70. Rios-Doria J, Day KC, Kuefer R, Rashid MG, Chinnaiyan AM, et al. (2003) The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. J Biol Chem 278: 1372-1379.
71. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, et al. (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438: 820-827.
72. Welch DR, Cooper CR, Hurst DR, Lynch CC, Martin MD, et al. (2008) Metastasis Research Society-American Association For Cancer Research Joint Conference on Metastasis. Cancer Res 68: 9578-9582. 68/23/9578.
73. Barkan D, Kleinman H, Simmons JL, Asmussen H, Kamaraju AK, et al. (2008) Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res 68: 6241-6250.